Announcement on Semi-annual Performance Forecast for 2026
Securities code: 603363 Securities abbreviation: Aonong Biotechnology Announcement number: 2026-048
Fujian Aonong Biotechnology Group Co., Ltd.
Semi-annual results forecast
2026
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The specific applicable situation of this performance forecast: net profit is negative.
The company expects to achieve a net profit attributable to shareholders of listed companies of -220 million in the first half of 2026
yuan to -150 million yuan.
The company expects to achieve a profit attributable to shareholders of listed companies after excluding non-recurring gains and losses in the first half of 2026.
Net profit ranges from -300 million yuan to -200 million yuan.
This performance forecast data is only preliminary accounting data. The specific data is based on the 2026 officially disclosed by the company.
The semi-annual report shall prevail. Investors are advised to pay attention to investment risks.
1. Performance forecast for this period
(1) Performance forecast period
January 1, 2026 to June 30, 2026.
(2) Performance forecast
Preliminary calculations by the company’s financial department:
The net profit attributable to shareholders of the listed company is expected to be between -220 million yuan and -150 million yuan in the first half of 2026.
It is expected that the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, in the first half of 2026 will be -300 million yuan to -200 million yuan.
(3) This performance forecast data has not been audited by a certified public accountant.
2. Performance of the same period last year
Total profit: 361.2594 million yuan. Net profit attributable to shareholders of the listed company: 360.8011 million yuan. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses: -29.743 million yuan.
Earnings per share: 0.14 yuan.
3. The main reasons for the expected loss in this period’s performance
The company expects a performance loss in the first half of 2026, mainly due to:
Affected by the fluctuation of the pig market, the sales price of pigs in this period is low, and the number of pigs slaughtered in this period has increased compared with the same period last year, and the pig breeding business has suffered a large loss.
The reorganization income in the same period last year was nearly 380 million yuan, and the reorganization income in this period decreased significantly.
The company's board of directors and management attach great importance to the current performance loss, and will continue to focus on the main business, deepen cost control, accelerate the coordinated development of the entire industry chain with "pig" as the core, strive to improve the company's profitability, and effectively protect the interests of investors.
4. Risk warning
This estimated performance data has not been audited by a certified public accountant and is a preliminary calculation made by the company's financial department based on its own professional judgment. The company has currently found no major uncertainties that affect the accuracy of this performance forecast.
5. Other explanations
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be subject to the company's officially disclosed semi-annual report for 2026. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Fujian Aonong Biotechnology Group Co., Ltd.
July 15, 2026